MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

Store in airtight containers and protect from light.

Provenance

This compatibility recommendation is derived from Thiamine 50mg tablets (Accord Healthcare Ltd).

Stability Notes

Store in airtight containers and protect from light.

Provenance

This compatibility recommendation is derived from Thiamine 100mg tablets (Accord Healthcare Ltd).

Stability Notes

Store in an airtight container and protect from light.

Provenance

This compatibility recommendation is derived from Baraclude 0.5mg tablets (Bristol-Myers Squibb Pharmaceuticals Ltd).

Stability Notes

Store in original package to protect from moisture.

Provenance

Compatibility information derived from CellCept 500mg tablets (Roche Products Ltd).

Stability Notes

Store in an airtight container and protect from moisture.

Provenance

This compatibility recommendation is derived from Gilenya 0.5mg capsules (Novartis Pharmaceuticals UK Ltd).

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Cyklokapron 500mg tablets (Viatris UK Healthcare Ltd).

Stability Notes

Protect from light.

Provenance

This compatibility recommendation is derived from Zanidip 20mg tablets (Recordati Pharmaceuticals Ltd).

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Mimpara 30mg tablets (Amgen Ltd).

Stability Notes

Store in airtight containers. Protect from light and moisture.

Provenance

This compatibility recommendation is derived from Galsya XL 16mg capsules (Krka UK Ltd) and Reminyl XL 16mg capsules (Takeda UK Ltd).

Stability Notes

Original pack contains a desiccant because topiramate is hygroscopic, therefore unsuitable for MCA.

Provenance

This compatibility recommendation is derived from Topiramate 50mg tablets (Milpharm Ltd) and Topamax 50mg tablets (Janssen-Cilag Ltd).

Print this list

Medicines under this category are suitable for use inside MCAs, although this is likely to be an off-label use.
Medicines under this category can theoretically be used inside an MCA; however, mitigations may need to be considered.
Medicines under this category are not suitable for use inside MCAs.
We do not have stability information for these medicines and therefore cannot make a recommendation on suitability in an MCA.